Methotrexate: Difference between revisions
(Add SMW Indications by Condition query table) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| Line 62: | Line 62: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
|mainlabel=- | |mainlabel=- | ||
Latest revision as of 21:57, 20 March 2026
Administration
- Type: Immunosuppressant/antineoplastic
- Dosage Forms:
- Routes of Administration: IV/IM, oral
- Common Trade Names: Trexall, Rheumatrex, Otrexup
Adult Dosing
Ectopic pregnancy
- Single-dose regimen: Methotrexate 50 mg/m2
Pediatric Dosing
Special Populations
- Pregnancy Rating: X
- Lactation risk: Infant risk has been determined (risk of serious adverse effects for infant)
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Breastfeeding, pregnant, or possibility of impregnating someone
- Blood dyscrasias
- Chronic liver disease
Adverse Reactions
Serious
- Hepatotoxicity
- Nephrotoxicity
- Myelosuppression, aplastic anemia, pancytopenia
- Infectious disease
- Tumor lysis syndrome
- GI bleed
- Neurotoxicity, seizure
- Pericardial effusion
- TEN
Common
- Nausea/vomiting, diarrhea
- Stomatitis
- Leukopenia, thrombocytopenia
- Alopecia, photosensitivity, rash
- Dizziness
Pharmacology
- Half-life: 8-15hr
- Metabolism: Extensive hepatic and intracellular
- Excretion: Mostly renal. Dialyzable.
Mechanism of Action
- Inhibits dihydrofolate reductase→ blocks DNA synthesis and thus, cellular replication/repair
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Ectopic pregnancy | 50 mg/m2 IM | Medical management (single dose regimen) | IM | Adult |